Medroxyprogesterone is an effective, fertility sparing treatment for endometrial cancer and atypical hyperplasia, but the recurrence rate is considerable

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1599, 2007-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Case report: ICSI outcome following conservative fertility sparing management of endometrial cancer

By Bozdag Gurkan   Yarali Hakan   Polat Mehtap   Esinler Ibrahim   Tiras Bulent   Ayhan Ali  

Reproductive BioMedicine Online, Vol. 18, Iss. 3, 2009-03 ,pp. : 416-420

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

The -blocker terazosin is effective in the treatment of benign prostatic hyperplasia

By  

Inpharma, Vol. 1, Iss. 1320, 2002-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Endometrial cancer risk with medroxyprogesterone appears to decrease with a greater number of days used per month

By  

Reactions Weekly, Vol. 1, Iss. 1027, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Ethinylestradiol: Breast cancer and endometrial hyperplasia in an elderly patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1363, 2011-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

KATP-channel openers for the treatment of breast and endometrial cancer

By  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 7, 2002-07 ,pp. : 1111-1113

Informa Healthcare

Access to resources Recommend Favorite